Abstract
Summary
The compound, N-benzyl-N-methyl-2-propynylamine - HC1 (MO-911), is shown to be a potent monoamine oxidase inhibitor in man, with hypotensive properties. Since its structure is different from that of previous inhibitors, the findings support the hypothesis that effective inhibition of monoamine oxidase results in orthostatic lowering of blood pressure, presumably by selective decrease of sympathetic nerve activity. Extensive clinical trial of the drug as an antihypertensive agent is warranted.
Get full access to this article
View all access options for this article.